REGULATED INFORMATION
GHENT, Belgium, 16 June 2017 - Ablynx (([Euronext Brussels: ABLX, OTC:ABYLY) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from FMR LLC on 13 June 2017.
FMR LLC (taking into account the holdings of its subsidiary undertakings) currently holds a total of 5,620,583 Ablynx shares, representing 9.19% of the current 61,133,199 outstanding Ablynx shares, slightly increased from 9.14% previously.
FMR LLC has notified Ablynx that the shareholding in Ablynx held through financial instruments by FMR Co., Inc., a subsidiary of Fidelity Management & Research Company, which itself is a subsidiary of FMR LLC (the ultimate parent company), has dropped below the 3% threshold as of 9 June 2017.
According to the notification, FMR Co., Inc.'s holding of Ablynx shares and voting rights through financial instruments has decreased to 1,827,367 shares, corresponding to 2.99% of the current 61,133,199 outstanding Ablynx shares (versus 3.35% in the previous notification on 28 December 2016).
The notified details are presented below:
| Name | % of shares and voting rights | % of shares and voting rights held through financial instruments | Total of both | |||
| Shares | Voting rights | Shares | Voting rights | Shares | Voting rights | |
| FMR LLC Fidelity Management & Research Company FMR Co., Inc. | 3.61% | 3.61% | 2.99% | 2.99% | 6.60% | 6.60% |
| FMR LLC FIAM Holdings Corp. Fidelity Institutional Asset Management Trust Company | 1.50% | 1.50% | 1.50% | 1.50% | ||
| FMR LLC FIAM Holdings Corp. FIAM LLC | 1.10% | 1.10% | 1.10% | 1.10% | ||
| TOTAL | 6.20% | 6.20% | 2.99% | 2.99% | 9.19% | 9.19% |
The holdings attributable to FMR LLC arise from holdings of various undertakings for collective investment that are managed by FMR Co., Inc., Fidelity Institutional Asset Management Trust Company and FIAM LLC, each of which are entities that are subsidiaries of, and controlled by, FMR LLC. These undertakings for collective investment have granted FMR LLC discretionary power to vote the securities in accordance with the FMR LLC board proxy voting policy. FMR LLC is not a controlled undertaking.
Full versions of all transparency notifications are available on Ablynx website, under the section Investors.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Lies Vanneste
Director Investor Relations
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e: lies.vanneste@ablynx.com
Follow us on Twitter @AblynxABLX
Ablynx media/analyst relations
FTI Consulting:
Julia Phillips, Brett Pollard, Mo Noonan
t: +44 20 3727 1000
e: ablynx@fticonsulting.com
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/bd1dae0c-b913-47a7-8061-83c6fe891dba
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
